Sentiment Trading

Regeneron Pharmaceuticals acquires 23andMe for $256 million, aiming to advance shared goals of improving human health and wellness while prioritizing customer data privacy and security.

Regeneron Pharmaceuticals Inc. saw its stock plummet 9-10% after missing earnings expectations, driven by lower-than-expected demand for its flagship product Eylea.

Regeneron Pharmaceuticals Inc. saw its stock plummet 9-10% after missing earnings expectations, driven by lower-than-expected demand for its flagship product Eylea.

Regeneron Pharmaceuticals Inc. saw its stock plummet 10% after a disappointing earnings report, driven by lower-than-expected demand for its flagship product Eylea, which is crucial to the company’s financial health.

Regeneron Pharmaceuticals Inc. made significant strides in the first quarter of 2025, with notable developments in oncology and ophthalmology, solidifying its position as a leader in the biotechnology industry.